Endobronchial coil treatment in severe emphysema patients with alpha-1 antitrypsin deficiency

Figures & data

Table 1 Characteristics, coil treatment, changes at 6 and 12 months, and 1-year adverse events in AATD patients included in the REVOLENS study

Variable	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6
Age (years), sex (M/F)	48, M	57, F	39, M	64, M	47, M	61, M
BMI (kg⋅m^−2)	23.7	20.3	27.8	24.1	25.1	21.8
Pack-years smoking	26	24	20	40	16	15
Augmentation therapy	No	Yes	No	Yes	Yes	Yes
Lobe, n coils  First  Second	RLL, 12 LLL, 10	RLL, 10 LUL, 12	RLL, 10 LLL, 11	RUL, 12 LUL, 10	RUL, 10 LUL, 10	RUL, 10 LUL, 9
FEV1, L(%)  Changes at 6 Mo, L  Changes at 12 Mo, L	0.68 (18) −0.05 −0.02	0.82 (32) +0.06 −0.13	1.22 (29) −0.25 −0.23	0.62 (20) +0.28 +0.26	0.96 (25) +0.08 −0.09	0.81 (26) −0.01 −0.07
RV, L(%)  Changes at 6 Mo, L  Changes at 12 Mo, L	6.51 (304) −0.42 −0.63	5.44 (284) +0.76 −0.32	5.68 (284) −0.5 +0.62	7.29 (300) −2.42 −1.09	6.2 (299) −0.04 −0.04	5.94 (256) −0.45 −0.47
6MWT, m  Changes at 6 Mo, m  Changes at 12 Mo, m	433 −31 −39	423 −3 −13	482 +6 +49	108 +102 −48	420 0 0	264 −114 −24
SGRQ, points  Changes at 6 Mo, L  Changes at 12 Mo, L	48 −10 −10	39 −2 −2	25 −6 −6	88 +1 +2	47 −6 −5	62 −9 −11
SAEs (in 1 year)  Pneumonia  Other	0	0	0	2 1a 1b	0	0
Non-SAEs (in 1 year)  COPD exacerbation  Pneumonia  Mild hemoptysis  Other respiratory  Non-respiratory	3 1 0 0 1 1	6 3 0 0 3 0	0 0 0 0 0 0	5 4 0 0 1 0	12 4 2 2 1 3	3 2 0 1 0 0

Notes:

a Pneumonia 6 days after the first coil treatment resolving with antibiotics and corticosteroids.

b One colonoscopy requiring hospitalization.

Abbreviations: AATD, alpha-1 antitrypsin deficiency; BMI, body mass index; F, female; LLL, left lower lobe; LUL, left upper lobe; M, male; Mo, months; RLL, right lower lobe; RUL, right upper lobe; RV, residual volume; SAEs, serious adverse events; SGRQ, St George’s Respiratory Questionnaire.

Table 2 Efficacy end points in AATD patients included in the REVOLENS study

Changes from baselinea	Alpha-1 antitrypsin patients (n=6)	Other patients (n=84)	P-value
6 months
6MWT, m	−2 [−114; +102]	+1 [−224; +205]	0.60b
FEV1, L	+0.03 [−0.25; +0.28]	+0.03 [−0.28; +0.59]	0.87b
RV, L	−0.44 [−2.42; +0.76]	−0.39 [−2.51; +1.41]	0.89b
SGRQ total	−6 [−10; +1]	−8 [−47; +35]	0.59b
12 months
6MWT, m	−19 [−48; +49]	0 [−200; +188]	0.57b
FEV1, L	−0.08 [−0.23; +0.26]	+0.02 [−0.37; +0.59]	0.10b
RV, L	−0.40 [−1.09; +0.62]	−0.41 [−2.77; +2.45]	0.85b
SGRQ total	−6 [−11; +2]	−5 [−47; +32]	0.99b

Notes:

a Data are expressed as median [range].

b Wilcoxon test.

Abbreviations: AATD, alpha-1 antitrypsin deficiency; RV, residual volume; SGRQ, St George’s Respiratory Questionnaire.